Strs Ohio Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN

Strs Ohio cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% during the 1st quarter, HoldingsChannel reports. The firm owned 31,656 shares of the biopharmaceutical company’s stock after selling 1,340 shares during the period. Strs Ohio’s holdings in Regeneron Pharmaceuticals were worth $24,459,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. WPG Advisers LLC lifted its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Board of the Pension Protection Fund purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Leerink Partners reissued a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Finally, Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $654.27 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $532.60 and a one year high of $821.11. The business’s fifty day moving average is $652.48 and its 200 day moving average is $725.50. The stock has a market capitalization of $69.17 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.22 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.